Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
- V. A. Papadimitrakopoulou
- , T. S. Mok
- , J. Y. Han
- , M. J. Ahn
- , A. Delmonte
- , S. S. Ramalingam
- , S. W. Kim
- , F. A. Shepherd
- , J. Laskin
- , Y. He
- , H. Akamatsu
- , W. S.M.E. Theelen
- , W. C. Su
- , T. John
- , M. Sebastian
- , H. Mann
- , M. Miranda
- , G. Laus
- , Y. Rukazenkov
- , Y. L. Wu
- University of Texas Health Science Center at Houston
- Chinese University of Hong Kong
- National Cancer Center
- Sungkyunkwan University
- IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
- Emory University
- University of Ulsan
- Princess Margaret Cancer Centre
- University of Toronto
- Provincial Health Services Authority
- Daping Hospital, the Third Military Medical University
- Wakayama Medical University
- Netherlands Cancer Institute
- National Cheng Kung University
- Olivia Newton-John Cancer Research Institute
- Goethe University Frankfurt
- AstraZeneca
- Guangdong Academy of Medical Sciences
Research output: Contribution to journal › Article › peer-review
253
Link opens in a new tab
Scopus
citations